study designs evaluating safety and efficacy of elezanumab in 2 MS patient populations with different underlying pathologies: relapsing (RMS) and progressive (PMS) forms of MS.Background: Disease-modifying therapies and symptom management are current standard of care for multiple sclerosis (MS) ...
BackgroundElezanumab is a fully humanized monoclonal antibody directed against repulsive guidance molecule A (RGMa). Studies in patients with multiple sclerosis (MS) demonstrate RGMa upregulation, which inhibits axonal growth and myelination, oligodendroglial regeneration and functional recovery after trau...
Studies in patients with multiple sclerosis (MS) demonstrate RGMa upregulation, which inhibits axonal growth and myelination, oligodendroglial regeneration and functional recovery after trauma or inflammation. Elezanumab treatment promoted axon regeneration, neuroprotection, remyelination, and immune ...
Elezanumab is a monoclonal antibody that neutralizes the neurite outgrowth inhibitor, repulsive guidance molecule A (RGMa), and may promote neurorestoration and neuroprotection.Design/Methods: RADIUS-R (NCT03737851) and RADIUS-P (NCT03737812) are RAndomized, Double-blind, placebo-controlled, multIple...
Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows to intervention (TTI), and restrictive patient ...